Adjuvant treatment for Stage i seminoma: Why radiotherapy is better than carboplatin

Prahlad Yathiraj, Krishna Sharan, Donald Fernandes, M. Vidyasagar

Research output: Contribution to journalReview article

Abstract

Adjuvant treatment options for Stage I seminoma include active surveillance, chemotherapy, and radiotherapy. Active surveillance may not be ideal for the average Indian patient. Of the two accepted adjuvant therapy options, namely single-dose carboplatin chemotherapy and radiotherapy to the retroperitoneal nodes, though it intuitively appears more appealing, a deeper review reveals the potential drawbacks of chemotherapy. This article highlights the misconceptions regarding carboplatin and provides reasons for an argument why radiotherapy is better when a patient with Stage I seminoma chooses to undergo adjuvant treatment.

Original languageEnglish
Pages (from-to)1216-1219
Number of pages4
JournalJournal of Cancer Research and Therapeutics
Volume12
Issue number4
DOIs
Publication statusPublished - 01-10-2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Adjuvant treatment for Stage i seminoma: Why radiotherapy is better than carboplatin'. Together they form a unique fingerprint.

  • Cite this